INS and type 1 diabetes mellitus: Continuous glucose monitoring (CGM) metrics and insulin delivery data were analyzed across the first 3 months of use and between pediatric age groups (<6-year-olds, 6 to <12-year-olds, and 12 to <18-year-olds).<h4>Results</h4>Among 74 youth initiating Omnipod 5 within 90 days of T1D diagnosis, there was no occurrence of DKA or severe hypoglycemia in the first 3 months of AID system use.